All articles by Clare Sansom – Page 3

  • 0912CW_FEATURE_TBDrugs_Fig1_630
    Feature

    The latent threat of tuberculosis

    2012-08-15T00:00:00Z

    Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease

  • Feature

    Climbing the data mountain

    2011-12-22T12:22:11Z

    Clare Sansom takes a 'peak' at the databases that stop researchers being buried under an avalanche of chemical information

  • Feature_Alzheimers_MainImage_410
    Feature

    Turning the tables on Alzheimer's

    2011-06-30T11:47:00Z

    As our understanding of Alzheimer's disease develops, Clare Sansom takes a look at emerging strategies for treating this enigmatic illness

  • Feature

    Fighting the flu

    2011-01-31T11:43:44Z

    The threat of pandemic influenza is constantly on the horizon. Clare Sansom explores the latest attempts to tackle an ever-changing foe

  • FEATURE-GPCR-300
    Feature

    Receptive receptors

    2010-07-30T09:11:00Z

    One route to developing new drugs is to look at targeting the hundreds of G-protein-coupled receptors that are not currently exploited clinically. Clare Sansom investigates

  • Feature

    Model molecules

    2010-03-31T09:51:37Z

    As computational chemistry's footprint expands, Clare Sansom considers the technical challenges that remain

  • FEATURE-HIV-protease-350
    Feature

    Molecules made to measure

    2009-10-28T10:47:00Z

    HIV protease inhibitors have been one of the big successes of rational drug design. Clare Sansom looks at the impact of structural biology on drug discovery

  • Feature

    Temozolomide - birth of a blockbuster

    2009-06-26T15:27:00Z

    The history of anticancer drug temozolomide can be traced back over 30 years - and it all started with some novel nitrogen chemistry, says Clare Sansom

  • Feature

    Structuring Europe

    2008-11-27T11:24:00Z

    Not every country in Europe can afford a synchrotron. So as new member states join, how is EU funding getting the best out of research across the continent? Clare Sansom reports